The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

Investment analysts at William Blair upped their FY2024 EPS estimates for Kezar Life Sciences in a note issued to investors on Wednesday, November 13th. William Blair analyst M. Phipps now expects ...

There are multiple chapters near you. Select your preferred chapter.

WASHINGTON -- Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are ...

The FDA told the San-Francisco based biotech to halt the PALIZADE study (NCT05781750), a Phase IIb trial investigating ...

The agency has placed a partial hold on the phase 2a PORTOLA trial evaluating the selective immunoproteasome inhibitor ...

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics ...

The Lupus Research Alliance (LRA) is excited to announce the first-ever recipients of the Translational Bridge Award (TBA), ...

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Kezar Life Sciences, Inc. (Nasdaq: KZR) concerning the Company and its directors’ and ...

The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that a total of 33 studies, funded by the organization or supported by its clinical research ...

Abstract #2580: Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study 2:15-2:30 PM Room 146AB Tuesday ...

(Reuters) -The U.S. Food and Drug Administration has placed a clinical hold on Kezar Life Sciences (NASDAQ:KZR)' trial of experimental drug for lupus, the company said on ...